A study, published in Molecular Psychiatry, led by Prof. Bernard Lerer from the Department of Psychiatry at the Hadassah—Hebrew University Medical Center shows promising results for using psilocybin, a psychedelic compound, as a potential treatment for obsessive-compulsive disorder (OCD) and Tourette’s syndrome. The paper is titled “Striking Long Term Beneficial Effects of Single Dose Psilocybin and Psychedelic Mushroom Extract in the SAPAP3 Rodent Model of OCD-Like Excessive Self-Grooming.”
Psilocybin shows promise as new treatment for OCD and Tourette’s syndrome, finds study
-
HighlightsFree Dark Web Monitoring Stamps the $17 Million Credentials Markets
-
HighlightsSmart buildings: What happens to our free will when tech makes choices for us?
-
AppsScreenshots have generated new forms of storytelling, from Twitter fan fiction to desktop film
-
HighlightsDarknet markets generate millions in revenue selling stolen personal data, supply chain study finds
-
SecurityPrivacy violations undermine the trustworthiness of the Tim Hortons brand
-
Featured HeadlinesWhy Tesla’s Autopilot crashes spurred the feds to investigate driver-assist technologies – and what that means for the future of self-driving cars
